Newsroom

Latest Press Releases

February 6, 2019
Arch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO-176, an Anti-CD47 Antibody with a Best-in-class Profile

Poster Presentations

60th ASH Annual Meeting & Exposition

December 1, 2018

Poster Presentation: Therapeutic potential of AO-176, a next-generation humanized CD47 antibody, for hematologic malignancies

30th EORTC-NCI-AACR Symposium

November 13, 2018

Poster Presentation: Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anti-cancer properties and negligible binding to red blood cells

SITC 2018 33rd Annual Meeting

November 7, 2018

Poster Presentation: AO-176, next-generation CD47 antibody, induces immunogenic cell death

Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

September 30, 2018

Poster Presentation: AO-176, next-generation CD47 antibody, induces immunogenic cell death

AACR Annual Meeting 2018

April 14, 2018

Poster Presentation: AO-176, a humanized anti-CD47 monoclonal antibody that directly kills human tumor cells and has additional unique functional characteristics